Claims
- 1. A compound, including resolved enantiomers and/or diastereomers, hydrates, salts, solvates or mixtures thereof, the compound having a straight or branched aliphatic hydrocarbon structure of formula I: ##STR108## wherein: n is an integer from one to four;
- m is an integer from six to twenty;
- independently, R.sub.1 and R.sub.2 are hydrogen, a straight or branched chain alkyl, alkenyl or alkynyl of up to twenty carbon atoms in length or --(CH.sub.2).sub.w R.sub.5, w being an integer from one to twenty and R.sub.5 being an hydroxyl, halo, C.sub.1-8 alkoxyl group or a substituted or unsubstituted carbocycle or heterocycle; or
- jointly R.sub.1 and R.sub.2 form a substituted or unsubstituted, saturated or unsaturated heterocycle having from four to eight carbon atoms, N being a hetero atom;
- R.sub.3 is hydrogen or C.sub.1-3 ; or
- jointly one of R.sub.1 or R.sub.2 and R.sub.3 form a substituted or unsubstituted linking carbon chain, having from one to four carbon atoms, joining the O and N in a cyclic structure, an integer sum equal to n+a number of carbon atoms in the linking carbon chain being less than six;
- a total sum of carbon atoms comprising R.sub.1 or R.sub.2, (CH.sub.2).sub.n and (CH.sub.2).sub.m does not exceed forty; and
- R.sub.4 is a substituted or unsubstituted carbocycle having one ring or two-fused rings, each ring having five or six ring atoms wherein a ring atom of the carbocycle is attached to a terminal carbon atom of (CH.sub.2).sub.m.
- 2. The compound of claim 1, wherein n is one or two.
- 3. The compound of claim 1, wherein m is an integer from six to ten.
- 4. The compound of claim 1, wherein m is an integer from ten to fourteen.
- 5. The compound of claim 1, wherein R.sub.5 substituents are selected from the group consisting of hydroxyl, chloro, fluoro, bromo, or C.sub.1-6 alkoxy, or a mono-, di- or tri-substituted carbocycle or heterocycle having from four to seven carbon atoms.
- 6. The compound of claim 1, wherein (CH.sub.2).sub.m is substituted by a halogen atom, an hydroxyl group, or substituted or unsubstituted C.sub.(1-10) alkoxyl, C.sub.(1-10) alkyl, C.sub.(2-10) alkenyl or C.sub.(1-10) alkynyl group.
- 7. The compound of claim 1, wherein the carbocycle is substituted with a member selected from the group consisting of C.sub.(1-4) alkyl, C.sub.(2-4) alkenyl, C.sub.(1-4) alkynyl, hydroxyl, carbonyl, amino, thio, thiol, thiocarbonyl and imino group and a single atom.
- 8. The compound of claim 7, wherein the single atom is selected from the group consisting of chlorine, bromine, fluorine and oxygen.
- 9. The compound of claim 1, wherein bonds of the carbocycle are saturated or the carbocycle has at least one unsaturated carbon-carbon bond.
- 10. The compound of claim 1, wherein the ring atoms are carbon atoms.
- 11. The compound of claim 10, wherein the carbocycle is selected from the group consisting of phenyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cycloheptyl, cycloheptenyl, biscyclooctyl, indanyl, indenyl, decalinyl, resorcinolyl, tetralinyl, .alpha.-tetralonyl, 1-indanonyl, cyclohexanedionyl and cyclopentanedionyl.
- 12. The compound of claim 1, wherein at least one ring of the carbocycle comprises at least five atoms.
- 13. The compound of claim 1, wherein the carbocycle is selected from the group consisting of: octylcarboxarnidobenzenyl, methylcarboxamidobenzenyl and dihydroxybenzenyl.
- 14. The compound of claim 1, wherein the terminal moiety has at least one substituent bonded to at least one ring of the carbocycle the at least one substituent being bonded to a carbon ring atom of the at least one ring by an sp.sup.2 bond and the carbon ring atom being adjacent to a carbon atom of the ring.
- 15. A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable excipient, the pharmaceutical composition being formulated for oral, parenteral, ex vivo or topical administration to a patient.
- 16. The composition of claim 15, wherein an oral dose of compound is from about 50 mg to about 1500 mg, twice or three times daily, a parenteral dose is from about 1.0 g to about 5.0 g administered (i.v., i.p., i.m., or s.c.) over a course of 24 hours, a topical formulation is from about 1% to about 4% concentration by weight, and the ex vivo culture concentration is from about 10 mM to about 500 mM.
- 17. The compound of claim 1, wherein the compound is selected from the group consisting of: ##STR109##
- 18. A compound having the formula: ##STR110##
Parent Case Info
This is a division of U.S. application Ser. No. 08/303,842, filed Sep. 8, 1994, U.S. Pat. No. 5,641,783, which is a continuation-in-part of application Ser. No. 08/152,650, filed Nov. 12, 1993, and application Ser. No. 08/164,081, filed Dec. 8, 1993, now U.S. Pat. No. 5,470,878, which are continuation-in-part application of application Ser. No. 08/040,820, filed Mar. 31, 1993, now abandoned.
US Referenced Citations (12)
Foreign Referenced Citations (11)
Number |
Date |
Country |
113102 |
Jul 1984 |
EPX |
132366 |
Jan 1985 |
EPX |
335723 |
Oct 1989 |
EPX |
2000943 |
Sep 1969 |
FRX |
2659241 |
Jul 1978 |
DEX |
8090687 |
Jun 1983 |
JPX |
256428 |
Feb 1990 |
JPX |
1119836 |
Jul 1968 |
GBX |
1119835 |
Jul 1968 |
GBX |
1356789 |
Jun 1974 |
GBX |
2096606 |
Oct 1982 |
GBX |
Non-Patent Literature Citations (4)
Entry |
Fuhrer et al., ".beta.--Adrenergic Blocking Agents: Substituted Phenylalkanolamines. Effect of Side-Chain Length on .beta.Blocking Potency InVitro." J. Med. Chem. vol. 27, 1984 p. 831. |
Bianco et al., Blood, 76:Supplement 1 (522), p. 133a, "Pentoxifylline (PTX) and GM-CSF Decrease Tumor Necrosis Factor-ALPHA (TNF-.alpha.) Levels in Patients Undergoing Allogeneic Bone Marrow Transplantation (BMT)," 1991. |
Davis et al., Applied Environment Microbial., 48:2, pp. 327-331, "Microbial Models of Mammalian Metabolism: Microbial Reduction and Oxidation of Pentoxifylline," Aug. 1984. |
Fuhrer et al., J. Med. Chem., vol. 27, pp. 831-836, ".beta.-Adrenergic Blocking Agents: Substituted Phenylalkanolamines. Effect of Side-Chain Length on .beta.-Blocking Potency in Vitro", 1984. |
Divisions (1)
|
Number |
Date |
Country |
Parent |
303842 |
Sep 1994 |
|
Continuation in Parts (2)
|
Number |
Date |
Country |
Parent |
152650 |
Nov 1993 |
|
Parent |
040820 |
Mar 1993 |
|